Hepatitis C virus (HCV) infection is associated with tremendous morbidity and mortality due to liver complications. HCV infection is also associated with many extrahepatic manifestations including cardiovascular diseases, glucose metabolism impairment, cryoglobulinemia vasculitis, B cell non Hodgkin lymphoma and chronic kidney disease (CKD). Many studies have shown a strong association between HCV and CKD, by reporting (i) an increased prevalence of HCV infection in patients on hemodialysis, (ii) an increased incidence of CKD and proteinuria in HCV infected patients, and (iii) the development of membranoproliferative glomerulonephritis secondary to HCV-induced cryoglobulinemia vasculitis. The HCV seropositivity is found to be associated to an increased relative risk for all-cause and cardiovascular mortality in dialysis population. HCV seropositivity is linked to lower patient and graft survival after kidney transplantation. Such poor HCV-associated prognosis should have encourage clinicians to treat HCV in CKD patients. However, due to frequent side effects and poor efficacy of interferon-based treatments, very few HCV dialysis patients have received HCV medications until now. The emergence of new direct acting, interferon-free antiviral treatment, leading to HCV cure in most cases with a satisfactory safety profile, will shortly modify the management of HCV infection in CKD patients. In patients with a glomerular filtration rate (GFR) >30 mL/min, the choice of DAA is not restricted.
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In those with 30>GFR>15 mL/min, only Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir or Grazoprevir plus Elbasvir regimen are approved. In patients with end stage renal disease (GFR< 15 mL/min or dialysis), current data only allow to use Grazoprevir plus Elbasvir combination. No doubt these data will be modified in the future with the advent of new studies including larger cohorts of HCV patients with renal impairment.
Abstract: 272 words
Approximately 130-170 million people are infected with hepatitis C (HCV) worldwide, 2.35% of the total world population. HCV has induced tremendous morbidity and mortality mainly due to liver complications (cirrhosis, hepatocellular carcinoma). In addition, many extrahepatic manifestations have been reported to be associated to chronic HCV infection with increased related morbidity and mortality including cardiovascular diseases, type 2 diabetes and insulin resistance, neurocognitive dysfunction, systemic vasculitis, B cell non Hodgkin lymphoma and chronic kidney disease [1, 2] . Patients chronically infected by HCV do present a high risk of chronic renal impairment with increased morbidity and mortality linked to it. In addition, the presence of renal insufficiency, and even more if an end stage renal failure (ESRD) or a kidney transplant (KT), has long been a brake to use interferon (IFN) based treatment because of poor efficacy and tolerance. Today, new direct acting antiviral (DAA) treatments lead to HCV cure in most patients with a very good safety profile.
However, new challenges remain, particularly with regard to specific populations such as those with chronic kidney disease (CKD), ESRD or KT. Our review will focus on specificities of screening and treatment of such HCV infected patients with renal disease.
HCV and kidney disease

ESRD patients on regular dialysis showed high prevalence of HCV infection
In dialysis patients, the prevalence of HCV infection has evolved dramatically over the last ten years. [8] . These data were further confirmed by another recent study from Taiwan [9] . In a meta-analysis including 107,356 patients Fabrizi et al.
found that HCV positive serology was an independent risk factor for proteinuria [adjusted OR 1.508 (95%CI 1.19; 1.89), P =0.0001) [6] . Anti-HCV positivity was significantly associated with proteinuria, independently of common metabolic factors such as diabetes mellitus, arterial hypertension, obesity, and dyslipidemia [6, 10] .
On the other hand, eight studies with cross-sectional design (788,027 patients) did not find a significant relationship between positive HCV serologic status and increased prevalence of CKD (mainly defined by eGFR<60ml/min/1.73m 2 ), with an adjusted OR of 1.16 (95%CI 0.98; 1.33, P = NS) [6] . In a retrospective cohort consisting of 71,528 Veterans, after a 6 years follow-up, 2,589 individuals recently HCV seroconverted were less likely to develop advanced CKD after controlling for traditional risk factors (HR 0.86; 95%CI 0.79, 0.92). HCV status was not significantly associated with progressive CKD (HR 0.93; 95% CI 0.86, 1.00) [11] .
Overall, HCV infected patients appear at high risk for renal disease and therefore should probably benefit from close renal monitoring.
HCV mixed cryoglobulinemia vasculitis and kidney involvement
Mixed cryoglobulinemia vasculitis (CryoVas) is an immune complex small vessel vasculitis involving mainly the skin, the joints, the peripheral nerve system and the kidneys [20] . Adjusted multivariate regression analysis identified age previously described [21] . CD4 + CD25 + FoxP3 + regulatory T cells levels are significantly reduced [22] , which may account for the expansion of peripheral auto-reactive B-cell that leads to vasculitis. In a genome-wide association study significant associations were identified on chromosome 6 [23] . It has been shown a higher percentage of a particular allele of the promoter of the B-cell activating factor -known to be related to higher translational activity of the gene [24] -and different expression patterns on circulating lymphocytes of microRNAs [25] . In contrast, specific virological factors have not yet been identified. Other factors are related to the infection by HCV of peripheral blood mononuclear cells, including peripheral dendritic cells, monocytes, and macrophages [26] . A persistent viral stimulation enhances expression of lymphomagenesis-related genes, particularly the activation-induced cystidine deaminase which is critical for somatic hypermutation and could lead to polyclonal and later monoclonal expansion of B cells [27] . Under this trigger effect, oligo-or monoclonal IgM, that shares rheumatoid activity, is produced by a permanent clone of B cells which favors the appearance of immune-complexes, formed by circulating HCV, anti-HCV polyclonal IgG, and the monoclonal IgM itself. Due to the clonally restricted IgM, these cryoprecipitable immune-complexes also escape the erythrocyte transport system and directly impact hepatic and splenic macrophages, which are unable to process them due to abnormalities in the biogenesis of lysosomal enzymes [28, 29] . The same abnormality is likely to occur in monocytes which are found to be engulfed with cryoglobulins at the electron microscopy examination of affected glomeruli. A murine model of cryoglobulinemic MPGN shows that macrophage ablation confers protection from mesangial expansion and does not affect cryoglobulin removal [30] . Based on these pathogenic principles, it seems unlikely that in patients with HCV-CryoVasc and a MPGN antiviral agents alone can effectively interfere with the all the pathogenic pathways, supporting the use of immunosuppressive drugs to stop the immune-mediated injury.
Prognosis of HCV infected patients with renal disease
Impact of HCV chronic infection on extra-liver outcomes in ESDR patients and kidney transplant recipients
Anti-HCV-positive serologic status is significantly associated with lower survival rates in dialysis populations. A meta-analysis, including fourteen observational studies involving 145,608 patients on long-term dialysis, found HCV seropositivity to be associated to an adjusted relative risk (RR) for all-cause mortality of 1. 35 HCV infection was associated with an increased risk of arterial disease in patients on regular dialysis or kidney transplant recipient. After kidney transplantation, coronary flow reserve was significantly reduced in non-diabetic HCV patients compared with non-HCV patients [34] . HCV viremia was an independent factor of aortic stiffness in patients on regular dialysis [35] . A meta-analysis showed that HCV seropositivity is significantly linked to lower patient and graft survival after kidney transplantation. Another meta-analysis including eighteen studies showed that HCV-infected renal transplant recipients have worse outcomes (mortality and graft loss) than HCV-negative recipients [38] .
HCV infection has been identified as an independent risk factor for graft loss and mortality in kidney transplantation patients. In a very recent retrospective study performed by the National Kidney and Transplant Institute in Philippines, authors found that patient survival was significantly lower in the HCV-positive than in the HCV-negative group, with a mean duration of patient survival of 141 versus 155 versus months, respectively (p=0.05). The mean duration of kidney graft survival was 130 versus 137 months, respectively (NS). Shortand long-term outcomes including biopsy-proven acute rejection, transplant glomerulopathy, chronic allograft nephropathy, renal function, and proteinuria were similar in both groups [39] . In the largest published metaanalysis, a total of 8,348 HCV-infected renal transplant recipients (before or after kidney transplantation) were identified from 123,228 living and deceased renal transplant reciepients, as reported in 18 studies [38] . The combined hazard ratio in HCV-infected recipients was 1.69 (1.33-1.97, p < 0.0001) and 1.56 (1.22-2.004, p < 0.0001) times greater than that of HCV-negative recipients for mortality and graft loss, respectively.
Impact of chronic kidney disease on liver outcomes in HCV-infected patients
Several studies have suggested that ESRD patients on regular haemodialysis have lower liver fibrosis and inflammatory activity than matched controls without CKD [40] [41] [42] .
The risk of liver inflammation was reported to be four times lower in haemodialysis patients than in matched controls [43] . Many hypothesis have been proposed such as the passage or trapping of viral particles during the dialysis or the production of cytokines (interferon-alpha, hepatocyte growth factor) with antiviral activities during the haemodialysis sessions [44] . The kidney transplantation did not prove to accelerate HCV related liver injury. In a retrospective cohort of HCV infected patients, 77% of thirty one kidney recipients who underwent multiple liver biopsies showed stable or improved liver histology whereas 62% of thirteen ESRD non transplanted patients showed a worsening of the liver fibrosis score [45] . Similar results were found in fifty one KTR, in which liver fibrosis remained stable or improved in 60% of cases.
The controversial data may be related to the heterogeneous strength of immunosuppressive regimens across the studies. A low initial fibrosis stage and a high diversification of the HVR-1 region of HCV genome between the time of kidney transplantation and the first liver biopsy were independent factors associated with liver fibrosis regression [46] [47] [48] .
Treatment of HCV infection in patients with renal disease
In ESRD patients before kidney transplantation fibrillation with myocardial infarction, increased lipase, and acute myocardial infarction).
There were four deaths, none considered related to study drug. Common adverse events (mainly headache, nausea, and fatigue) occurred at similar frequencies in patients receiving active and placebo drugs [65] .
After kidney transplantation
Before the IFN-free DAA era, antiviral treatment was initiated before kidney transplantation due to an increased risk of allograft dysfunction/rejection with IFN-based therapy. A few studies have been conducted to evaluate the efficacy and the safety of DAAs after kidney transplantation. In two small size retrospective cohorts including mainly HCV genotype 1 kidney transplanted (50% with advanced liver fibrosis), the SVR12 was 100% in both studies with a good safety profile [66, 67] . In this population, careful monitoring of blood level of calcineurin inhibitors are recommended as decreased levels of calcineurin inhibitors have been observed requiring drug dose adjustment [66] . Of note, blood levels of calcineurin inhibitors remained decreased three months after DAAs discontinuation. In a phase 2, openlabel study, post-transplant patients with or without cirrhosis were randomized to receive Ledipasvir plus Sofosbuvir for either 12 weeks (n = 57) or 24 weeks (n = 57). The median time from transplant was 10 years out in the 12-week cohort and 12 years out in the 24-week cohort. Overall, 100% of the 12-week cohort achieved SVR12 and 96% of those in the 24- week cohort [68] .
The particular case of HCV cryoglobulinemia vasculitis with renal involvement
Most HCV-Cryovas manifestations respond, at least partially, to clearance of HCV [79] . A full or partial clinical response of CryoVas symptoms was obtained in 91% of patients and a complete or partial immunological response in 81%. A full or partial renal response was noted in 80% with a decrease of creatinemia from 104 to 95 micromol/l, of proteinuria from 3.0 to 0.65 g/l as well as a decrease of hematuria. A serious adverse event was reported in only 12%.
Conversely, Cornella et al reported on five patients with HCV-CryoVas who received 24 weeks of triple therapy with PegIFN/ribavirin plus DAA (boceprevir, telaprevir or sofosbuvir). They found a good impact on main CryoVas manifestations but did not observe a rapid clearance of serum cryoglobulins [80] .
Despite the unquestionable evidence of a viral etiology and the role of effective antivirals, immunosuppression is still regarded as a major treatment in HCV-CryoVas patients with renal involvement. In case of severe CryoVas with renal involvement or in patients with failure or contraindication to antiviral treatment, Rituximab -a monoclonal anti-CD20 antibody -targets activated B-cells, which are responsible for cryoglobulin production and finally Cryovas lesions. iRtuximab has a better efficacy than conventional immunosuppressive treatments (i.e., glucocorticoids, azathioprine, cyclophosphamide, or plasmapheresis) or placebo [11, 66] . Addition of rituximab to peg-IFN/ribavirin led to a shorter time to clinical remission, better renal response rate, and higher rates of cryoglobulin clearance [12, 14] . Of note, some patients may experience a severe flare of CryoVas after rituximab infusion, notably patients with high cryoglobulin levels [82] . The cumulative probability of survival in patients with CryoVas MPGN was less than 60% at 5 years and most deaths in the pre-Rituximab era were due to liver failure and infections [83, 84] . A recently reported cohort of patients treated with an intensive "4 plus 2 Rituximab infusion protocol" showed a 75% survival rate at 6 years, with a 60% probability of remaining symptom-free for 10 years without any therapy [85] .
Corticosteroids, used alone or in addition to IFN, did not favourably affect the response of HCV-CryoVas manifestations in controlled studies [86] . Plasmapheresis offers the advantage of removing the pathogenic cryoglobulins from the circulation. It is particularly effective for rapidly progressive glomerulonephritis. Immunosuppressive therapy is usually needed with plasma exchange in order to avoid the rebound increase in cryoglobulin serum level seen after discontinuation of apheresis. When used in combination with HCV treatment, plasmapheresis did not modify the virologic response if IFN was given after each plasma exchange session [87] . There is no available data to date with DAA.
Care of HCV in patients with chronic kidney disease in daily practice
Screening
Altogether, many studies provide convincing data that suggest (i) a high prevalence of [85] . In such cases, an unsolved issue is the time when to start DAAs, i.e. during or after the critical phase.
c. When to treat? Before the onset of DAA, experts recommended to treat HCV in patients with ESRD before kidney transplantation due to the risk of kidney transplant dysfunction or rejection with IFN-based therapy. Preliminary results of small cohorts suggest the safety and efficacy of DAA in KT. On one hand, potential drug-drug interactions with immunosuppressants used after KT, the efficacy and safety of some DAA combinations in patients with severe CKD and the worsening prognosis of CKD patients with HCV, may encourage clinicians to treat HCV patients with CKD as soon as possible, i.e. before kidney transplantation. On the other hand, there is a possibility of treating after kidney transplantation when the use of organs from HCV positive donors is a common practice.
In summary, many studies support the strong association between HCV and CKD, by reporting (i) an increased HCV infection prevalence in patients on hemodialysis, (ii) an increased incidence of CKD in HCV infected patients, and (iii) membranoproliferative glomerulonephritis secondary to HCV cryoglobulinemia vasculitis. In addition, HCV seropositivity is associated to increased risk for all-cause and cardiovascular mortality in dialysis population. It is linked to lower patient and graft survival after kidney transplantation.
The recent emergence of new direct acting IFN-free antivirals, enabling high cure rates even in patients with severe renal impairment with a satisfactory safety profile should lead in the very next future to major modifications in the screening and care of HCV infection in CKD patients. 
